Potential utility of radioprotective agents in the practice of nuclear medicine

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 6, 2009, Pages 723-731

  Hosseinimehr, Seyed Jalal ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Nuclear medicine; Radiation; Radiopharmaceuticals; Radioprotective

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTATE LU 177; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID TYROSINE 3 OCTREOTIDE Y 90; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 86; AMIFOSTINE; ARGININE; CAPTOPRIL; CRATAEGUS EXTRACT; ETIDRONIC ACID RE 186; FLAVONOID; HERBACEOUS AGENT; HESPERIDIN; IMMUNOMODULATING AGENT; IODINE 131; LEXIDRONAM SAMARIUM SM 153; LUTETIUM 177; LYSINE; MELATONIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY J591 LU 177; MONOCLONAL ANTIBODY J591 Y 90; PENTETREOTIDE IN 111; PILOCARPINE; RADIOPHARMACEUTICAL AGENT; RADIOPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; SAMARIUM 153; SUCCIMER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIOXIDANT ACTIVITY; BETA RADIATION; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHROMOSOME ABERRATION; CLINICAL TRIAL; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG RETENTION; DRUG UPTAKE; ERYTHROCYTE TRANSFUSION; GAMMA RADIATION; GASTROINTESTINAL TOXICITY; GENE MUTATION; GENOTOXICITY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERKALEMIA; IONIZING RADIATION; KIDNEY INJURY; LEUKOCYTE COUNT; LINEAR ENERGY TRANSFER; MEDICAL PRACTICE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROBLASTOMA; NEUTROPENIA; NONHUMAN; NUCLEAR MEDICINE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL SAFETY; ORAL MUCOSAL DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PROTECTION; REVIEW; SALIVARY GLAND DISEASE; SALIVARY GLAND DYSFUNCTION; SIALOADENITIS; SIDE EFFECT; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THYROID CANCER; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

CELL DEATH; DNA DAMAGE; ENVIRONMENTAL EXPOSURE; GAMMA RAYS; HUMANS; NEOPLASMS, SECOND PRIMARY; NUCLEAR MEDICINE; POSITRON-EMISSION TOMOGRAPHY; RADIATION PROTECTION; RADIATION-PROTECTIVE AGENTS; RADIOPHARMACEUTICALS; TECHNETIUM; X-RAYS;

EID: 73649131637     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2009.0635     Document Type: Review

References (74)

1. Turner ND, Braby LA, Ford J, et al. Opportunities for nutritional amelioration of radiation-induced cellular damage. Nutrition 2002;18:904.
2. Hosseinimehr SJ. Foundation review: Trends in the development of radioprotective agents. Drug Discov Today 2007; 12:794.
3. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration ofamifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000;18:2226.
4. Cassatt DR, Fazenbaker CA, Bachy CM, et al. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. Semin Radiat Oncol 2002;12(1 Suppl 1):97.
5. Seed TM. Radiation protectants: Current status and future prospects. Health Phys 2005;89:531.
6. Little JB. Radiation carcinogenesis. Carcinogenesis 2000;21: 397.
7. Prasad KN. Handbook of Radiobiology. Boca Raton, FL: CRC Press, 1995.
8. Saha GB. Fundamentals of Nuclear Pharmacy. New York: Springer, 1998.
9. Taibi NT, Aka P, Kirsch-Volders M, et al. Radiological effect of 99mtechnetium-MIBI in human peripheral blood lymphocytes: Ex vivo study using micronucleus=FISH assay. Cancer Lett 2006;233:68.
10. Merz T, Tatum J, Hirsch J. Technetium-99m-labeled lymphocytes: A radiotoxicity study. J Nucl Med 1986;27:105.
11. Yildirim M, Ikbal M, Tos T, et al. Genotoxicity of thallium- 201 in patients with angina pectoris undergoing myocardial perfusion study. Tohoku J Exp Med 2005;206:299.
12. Bozkurt G, Yuksel M, Karabogaz G, et al. Sister chromatic exchanges in lymphocytes of nuclear medicine physicians. Mutat Res 2003;535:205.
13. Kopjar N, Garaj-Vrhovac V. Assessment of DNA damage in nuclear medicine personnel-comparative study with the alkaline comet assay and the chromosome aberration test. Int J Hyg Environ Health 2005;208:179.
14. Chattel JF, Hoefnagel CA. Radionuclide therapy. The Lancet 1999;354:931.
15. Oyen WJG, Bodei L, Giammarile F, et al. Targeted therapy in nuclear medicine-current status and future prospects. Ann Oncol 2007;18:1782.
16. Brans B, Linden O, Giammarile F, et al. Clinical applications of newer radionuclide therapies. Eur J Cancer 2006;42:994.
17. Dahllof G, Borgstrom P, Lundell G, et al. Severe oral mucositis after therapeutic administration of [131I] MIBG in a child with neuroblastoma. Surg Oral Med Pathol Oral Radiol Endod 2001;92:420.
18. Wang KL, Lin LY, Chen PM, et al. Chronic myeloid leukemia after treatment with 131I for thyroid carcinoma. J Chin Med Assoc 2005;68:230.
19. Kumagai A, Reiners C, Drozd V, et al. Childhood thyroid cancers and radioactive iodine therapy: Necessity of precautions radiation health risk management. Endocr J 2007; 54:839.
20. Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 2006;115:607.
21. Verkooijn RBT, Smith JWA, Romijn JA, et al. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid. Eur J Endocrinal 2006;155:801.
22. Subramanian S, Goldstein D, Pariea L, et al. Second primary malignancy risk in thyroid cancer survivors: A systematic review and meta-analysis. Thyroid 2007;17:1277.
23. Held KD, Biaglow J. Mechanisms for the oxygen radicalmediated toxicity of various thiol-containing compounds in cultured mammalian cells. Radiat Res 1994;139:15.
24. Maisin JR. Bacq and Alexander award lecture chemical radioprotection: Past, present, and future prospects. Int J Radiat Biol 1998;73:443.
25. Brown DQ, Pittock JW, 3rd, Rubinstein JS. Early results of the screening program for radioprotectors. Int J Radiat Oncol Biol Biophys 1998;8:565.
26. Bohuslavizki KH, Klutmann S, Jenicke L, et al. Salivary gland protection by S-2-(3-aminopropylamino)-ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: Results obtained in a rabbit animal model and a double-blind multiarm trial. Cancer Biother Radiopharm 1999;14:337.
27. Bohuslavizki KH, Klutmann S, Brenner W, et al. Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment. Results of a double-blinded, placebocontrolled study in patients with differentiated thyroid cancer. Strahlenther Onkol 1999;175 (suppl 4):6.
28. Bohuslavizki KH, Klutmann S, Bleckmann C, et al. Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer. Strahlenther Onkol 1999;175:57.
29. Kutta H, Kampen U, Sagowski C, et al. Amifostine is a potent radioprotector of salivary gland in radioiodine therapy. Strahlenther Onkol 2005;181;237.
30. Aframian DJ, Helcer M, Livni D, et al. Pilocarpine for the treatment of salivary glands' impairment caused by radioiodine therapy for thyroid cancer. Oral Dis 2006;12:297.
31. Valdez IH, Wolff A, Atkinson JC, et al. Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer 1993;71:1848.
32. Gornitsky M, Shenouda G, Sultanem K, et al. Double-blind randomized, placebo-controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004;98:45.
33. Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: The role of pilocarpine. J Nucl Med 2008;49:546.
34. Alexander C, Bade JB, Schaefer A, et al. Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 1998;39:1551.
35. Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005;46:261.
36. Nwosu AC, Jones L, Vora J, et al. Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 2008;98:1053.
37. DuBois SG, Messina J, Maris JM, et al. Hematological toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol 2004;22: 2452.
38. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, et al. Radioimmunotherapy of prostate cancer using 90Y- and 177Lulabeled J591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity. Clin Cancer Res 2005;11:7195s.
39. Vallabhajosula S, Goldsmith SJ, Hamacher KA, et al. Prediction of myelotoxicity based on bone marrow radiationabsorbed dose: Radio immunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med 2005;46:850.
40. Rolleman EJ, Krenning EP, Bernard BF, et al. Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats. Eur J Nucl Med Mol Imaging 2007;34:219.
41. Brenner W, Kampen WU, von Forstner C, et al. High-dose treatment with (186)Re-HEDP or (153)Sm-EDTMP combined with amifostine in a rabbit model. J Nucl Med 2001; 42:1545.
42. Brenner W, Kampen WU, Brümmer C, et al. Myeloprotective effects of different amifostine regimens in rabbits undergoing high-dose treatment with 186-rhenium-(tin)1,1-hydroxyethylidene diphosphonate (186Re-HEDP). Cancer Biother Radiopharm 2003;18:887.
43. Tannehill SP, Mehta MP. Amifostine and radiation therapy: Past, present, and future. Semin Oncol 1996;23(4 Suppl 8):69.
44. Santini V, Giles FJ. The potential of amifostine: From cytoprotectant to therapeutic agent. Hematologica 1999;84: 1035.
45. Planting AS, Catimel G, de Mulder PH, et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. Ann Oncol 1999;10:693.
46. Moorin RE, Meyrick DP, Rose A. Preclinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy. Nucl Med Commun 2007;28: 261.
47. Van Eerd JE, Vegt E, Wetzels JF, et al. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. J Nucl Med 2006;47:528.
48. Breeman WA, Van der Wansem K, Bernard BF, et al. The addition of DTPA to [177Lu-OTA0, Tyr3] octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging 2003;30:312.
49. Rolleman EJ, Bernard BF, Breeman WA, et al. Molecular imaging of reduced renal uptake of radiolabelled [DOTA0, Tyr3]octreotate by the combination of lysine and Gelofusine in rats. Nuklearmedizin 2008;47:110.
50. Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37:847.
51. Valkema R, Pauwels SA, Kvols LK, et al. Long-term followup of renal function after peptide receptor radiation therapy with (90) Y-DOTA (0), Tyr (3)-octreotide, and (177) Lu- DOTA (0), Tyr (3)-octreotate. J Nucl Med 2005;1:83S.
52. Barone R, Borson-Chazot F, Valkema R, et al. Patientspecific dosimetry in predicting renal toxicity with (90)YDOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46 (Suppl 1):99S.
53. Jamar F, Barone R, Mathieu I, et al. 86Y-DOTA0)-D-Phe1- Tyr3-octreotide (SMT487)-a phase 1 clinical study: Pharmacokinetics, biodistribution, and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510.
54. Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study. Eur J Nucl Med Mol Imaging 2003;30:207.
55. Vegt E, Wetzels JF, Russel FG, et al. Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. J Nucl Med 2006;47:432.
56. Rolleman EJ, Forrer F, Bernard B, et al. Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2007;34:763.
57. Hosseinimehr SJ, Nemati A. Radioprotective effects of hesperidin against gamma irradiation in mouse bone marrow cells. Br J Radiol 2006;79:415.
58. Müller AC, Pigorsch S, Beyer C, et al. Radioprotective effects of amifostine in vitro and in vivo measured with the comet assay. Strahlenther Onkol 2004;180:517.
59. Devi, P. Bisht KS, Vinitha M. A comparative study of radioprotection by ocimum flanonoids and synthetic aminophenol protectors in the mouse. Br J Radiol 1998;71:782.
60. Provinciali M, Ciavattini A, Di Stefano G, et al. In vivo amifostine (WR-2721) prevents chemotherapy-induced apoptosis of peripheral blood lymphocytes from cancer patients. Life Sci 1999;64:1525.
61. Hosseinimehr SJ, Mahmoudzadeh A, Akhlagpour S. Captopril protects mice bone marrow cells against genotoxicity induced by gamma irradiation. Cell Biochem Funct 2007; 25:389.
62. Arora R, Gupta D, Chawla R, et al. Radioprotection by plant products: Present status and future prospects. Phytother Res 2005;19:1.
63. Hosseinimehr SJ. Natural products as potential of radioprotective agents [Persian]. J Mazand Univ Med Sci 2008; 17:175.
64. Hosseinimehr SJ, Tavakoli H, Pourheidari G, et al. Radioprotective effects of citrus extract against gamma-irradiation in mouse bone marrow cells. J Radiat Res 2003;44:237.
65. Hosseinimehr SJ, Azadbakht M, Mousavi SM, et al. Radioprotective effects of Hawthorn fruit extract against gamma irradiation in mouse bone marrow cells. J Radiat Res 2007; 48:63.
66. Jagetia GC. Radioprotective potential of plants and herbs against the effects of ionizing radiation. J Clin Biochem Nutr 2007;40:74.
67. Jagetia GC, Reddy TK. The grapefruit flavonone, naringin, protects against the radiation-induced genomic instability in the mice bone marrow: A micronucleus study. Mutat Res 2002;519:37.
68. Shimoi K, Masuda S, Furugori M, et al. Radioprotective effects of antioxidative flavonoids in g-ray. Carcinogenesis 1994;15:2669.
69. Ganasoundari A, Devi PU, Rao BS. Enhancement of bone marrow radioprotection and reduction of WR-2721 toxicity by Ocimum sanctum. Mutat Res 1998;397:303.
70. Vijayalaxmi, Reiter RJ, Tan DX, et al. Melatonin as a radioprotective agent: A review. Int J Radiat Oncol Biol Phys 2004;59:639.
71. Koc M, Taysi S, Buyukokuroglu ME, et al. Melatonin protects rat liver against irradiation-induced oxidative injury. J Radiat Res 2003;44:211.
72. Vijayalaxmi, Reiter RJ, Herman TS, et al. Melatonin and radioprotection from genetic damage: In vivo=in vitro studies with human volunteers. Mutat Res 1996;371:221.
73. Stickney DR, Dowding C, Garsd A, et al. 5-androstenediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression. Int Immunopharmacol 2006;6:1706.
74. Stickney DR, Dowding C, Authier S, et al. 5-androstenediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression. Int Immunopharmacol 2007;7:500.